Price (delayed)
$1.18
Market cap
$92.35M
P/E Ratio
6.94
Dividend/share
N/A
EPS
$0.17
Enterprise value
$61.34M
CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. CytomX is developing a novel class of investigational conditionally activated antibody therapeutics,
There are no recent dividends present for CTMX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.